## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.04 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-3.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($238.67)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Thrivent Financial for Lutherans Sells 236,009 Shares of Humana Inc. $HUM**
- Source: MarketBeat | 20251221T100805 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly reduced its stake in Humana Inc. by selling 236,009 shares, cutting its holdings by 93.2%. Despite this, other major institutions like Vanguard, Dodge & Cox, and State Street largely increased their positions, resulting in institutional investors and hedge funds owning 92.38% of Humana's stock. Humana reported strong Q3 earnings, exceeding analyst expectations, and declared a quarterly dividend of $0.885.

**2. Humana Inc. (NYSE:HUM) Given Average Recommendation of "Hold" by Analysts**
- Source: MarketBeat | 20251221T080801 | Neutral | Relevance: 100%
- Analysts have given Humana Inc. (NYSE:HUM) an average "Hold" rating, based on recommendations from twenty-one analysts with an average 12-month price target of $294.32, suggesting a 13% upside from Friday's opening price. The company surpassed Q3 earnings estimates with EPS of $3.24 and saw revenue increase by 11.1% year-over-year to $32.65 billion, also declaring a quarterly dividend of $0.885. Institutional investors hold a significant portion of the stock, while several research analysts recently adjusted their ratings and price targets for Humana.

**3. Humana Inc. $HUM Holdings Raised by Voya Investment Management LLC**
- Source: MarketBeat | 20251220T140800 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC significantly increased its stake in Humana Inc. by 84.3% during Q3, now owning 290,225 shares valued at approximately $75.5 million. Humana exceeded Q3 expectations with an EPS of $3.24 and revenue of $32.65 billion. The company maintains a "Hold" consensus analyst rating with a target price of $294.32, and recently declared a quarterly dividend of $0.885 per share.

**4. Behind the reported Humana Building deal (Access Louisville Podcast)**
- Source: The Business Journals | 20251222T115606 | Neutral | Relevance: 100%
- LBF Senior Reporter Joel Stinnett discusses the potential sale of the Humana Building, located at 500 W. Main Street, to be redeveloped as a large hotel. He shares insights into gathering sources for this developing story on the "Access Louisville" podcast. This deal is reportedly being finalized behind the scenes, potentially changing a significant downtown Louisville landmark.

**5. Texas Permanent School Fund Corp Sells 13,598 Shares of Humana Inc. $HUM**
- Source: MarketBeat | 20251222T100753 | Neutral | Relevance: 98%
- Texas Permanent School Fund Corp reduced its stake in Humana Inc. by 59.3%, selling 13,598 shares and retaining 9,345 shares worth approximately $2.285 million. Other institutional investors also adjusted their holdings in Humana. The company reported strong quarterly earnings, beating analyst estimates, and has a "Hold" consensus rating from analysts with an average price target of $294.32.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Morgan Stanley | $262 | $277 | -5% |
| 2025-12-05 | Jefferies | $313 | $253 | +24% |
| 2025-11-25 | Barclays | $234 | $245 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |
| 2025-12-05 | Jefferies | up | Buy |
| 2025-11-25 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.14M) |
| Sells | 6 ($1.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.04 suggests fair value with growth premium. Balance sheet: strong liquidity (2.0x). Analyst sentiment negative (2 target cuts vs 1 raises). Insider selling cluster ($1.5M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $31.0B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.04 |
| Forward P/E | 20.7 |
| Current P/E | 15.1 |
| YoY Growth | -27.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.4% to 0.9% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 (-1.9%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (1.00x), long-term trend not supportive. MACD histogram positive (1.07), confirming momentum. RSI neutral at 51. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.89% (CS: 57) | Neutral |
| RSI_14 | 51.1 | Neutral |
| MACD Histogram | 1.07 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 0.993x | Below |
| vs SMA200 | 0.997x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $257.77
- **Stop Loss:** $238.67 (7.4% risk)
- **Target:** $295.97 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 62
- **Position Value:** $15,981.74
- **Portfolio %:** 15.98%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*